Feb 15: EMD Serono, a Merck KGaA company, got a win Thursday as the FDA converted Tepmetkos February 2021 accelerated nod to full approval for adult non-small cell lung cancer (NSCLC) patients whose disease harbors mesenchymal-epithelial transition (MET) exon 14 skipping alterations
These findings show that NAMPT overexpression promotes self-renewal properties, resulting in stemness-like maintenance, which ultimately leads to increased migration, dedifferentiation, and CSC-dependent resistance to therapy
Bandelow B, Zohar J, Hollander E, Kasper S, Mller HJ
The SPION was modified to produce a drug carrier that used magnetism in the chemotherapy of skin cancer
Weeks 912: 1000 mcg (1.0 mg) once weekly